Kindeva to develop inhaled cannabinoid formulations for BOL Pharma

Kindeva Drug Delivery has announced a new agreement with Israeli medical cannabis company Breath of Life International (BOL Pharma) for development of formulations of several cannabinoids for delivery via Kindeva MDIs. The formulations will initially be for the purpose of feasibility studies. BOL intends to develop the MDIs for the treatment of CND conditions including autism spectrum disorder, epilepsy, and anxiety for the US, UK, and EU markets the company said.

BOL CEO Kfir Avraham commented, “We are excited to form a partnership with Kindeva Drug Delivery, formerly 3M Drug Delivery Systems, a recognized global leader in the development of complex drugs, to develop a best-in-class inhaler. By entering into this collaboration, BOL Pharma reaffirms its commitment to developing pharmaceutical-based cannabinoid products to address serious medical needs. This partnership, bringing together two leading companies, will provide a patient-centric solution to those at need.”

BOL Chief Medical Officer Boaz Hirshberg said, “With Kindeva as our partner, BOL pharma is committed to testing this best-in-class inhaler in clinical trials to establish the safety and efficacy in several unmet medical conditions in consultation with the FDA and EMA. This partnership will allow us to develop a platform that will deliver an accurate and consistent dose to patients. Furthermore, the rapid onset of action will provide an advantage, especially when dealing with severe pain.”

Kindeva CEO Aaron Mann said, “The BOL partnership demonstrates how broad and effective inhaled drug delivery can be. Applications for inhaled therapies go beyond respiratory diseases. In this case, we’re looking at the systemic delivery of drugs via the lungs. Due to heightened bioavailability compared to oral delivery, inhaled cannabinoids have the possibility to significantly reduce the dosage and reduce the variability currently observed with cannabinoid treatment, with the potential to also enhance the overall accuracy, safety and efficacy.”

Kindeva recently announced that it has begun construction on a new headquarters building that will include laboratory space.

Read the Kindeva Drug Delivery press release.